

Please delete claims 2-7.

1
A

REMARKS


This paper is being submitted preliminary to the examination of the above-referenced application. Claims 1-65 are pending. By this amendment, Applicants have amended claims 1, 35, 40, 42, 51, 54, and 63 and deleted claims 2-7 to remove claims to certain subject matter covered by the claims of U.S. Patent Application 09/785,059 in order to avoid any double patenting type obviousness issues. No new matter is introduced by these amendments.

In accordance with 37 C.F.R. § 1.121, Applicant has provided (1) accurate instructions to amend the claims, (2) replacement claims in clean form herein, and (3) another version of the amended claims marked up to show all the changes relative to the previous version, which appears on an attached page.

V. Conclusion

In view of the technical amendments and remarks made herein, Applicants respectfully submit that the claims are presently in condition for allowance. Favorable consideration of this application is therefore earnestly solicited.

Respectfully submitted,



Rochelle K. Seide
Patent Office Reg. No. 32,300

Alicia A. Russo
Patent Office Reg. No. 46,192

30 Rockefeller Plaza, 45th floor
New York, New York 10112-4498
Attorneys for Applicants
(212) 408-2627

VERSION WITH MARKINGS TO SHOW CHANGES MADE**IN THE CLAIMS**

Please rewrite claims 1, 35, 40, 42, 51, 54, and 63 as follows:

And 1. A peptide having an amino acid sequence selected from the group consisting of:

[RVIRVVQRACRAIRHIVRRIRQGLRRIL (SEQ ID NO: 1);

RVIRVVQRACRAIRHIVRRIRQGLRRILRVV (SEQ ID NO: 2);

RWIRVVQRWCRAIRHIWRRIRQGLRRWLRVV (SEQ ID NO: 3);]

RVVRVVRVVR (SEQ ID NO:4) ;

RRVVRVVRVVRVVRVVRVVRVVR (SEQ ID NO: 5);

VRRVVRVVRVVRVVRVVRVVRVVRVVRVVRVVRVVR (SEQ ID NO: 6);

RRVVRVVRVVRVVRVVRVVRVVRVVRVVRVVRVVRVVRVVRVVRVVR (SEQ ID NO:7);

RVVRVVRVVRVVRVVRVVRVVRVVRVVRVVRVVRVVRVVRVVRVVR (SEQ ID NO:8);

RVVRVVRVVR (SEQ ID NO:9);

RRWVRVVRVVRVVRVVRVVRVVRVVR (SEQ ID NO:10);

VRRVVRVVRVVRVVRVVRVVRVVRVVRVVRVVRVVRVVRVVRVVRVVR (SEQ ID NO:11); and

RVVRVVRVVRVVRVVRVVRVVRVVRVVRVVRVVRVVRVVRVVRVVR (SEQ ID NO:12).

35. A solid phase substrate comprising at least one peptide selected from the group consisting of:

[RVIRVVQRACRAIRHIVRRIRQGLRRIL (SEQ ID NO: 1);

RVIRVVQRACRAIRHIVRRIRQGLRRILRVV (SEQ ID NO: 2);

RWIRVVQRWCRAIRHIWRRIRQGLRRWLRVV (SEQ ID NO: 3);]

RVVRVVRVVR (SEQ ID NO:4[;]);

RRVRRVRRVRRVRRVRRVRRVRR (SEQ ID NO: 5);

VRRVRRVRRVRRVRRVRRVRRVRRVRRVRRVRRVRRVRR (SEQ ID NO: 6);

RRVRRVRRVRRVRRVRRVRRVRRVRRVRRVRRVRRVRRVRRVRRVRR (SEQ ID NO:7);

RVRRVRRVRRVRRVRRVRRVRRVRRVRRVRRVRRVRRVRRVRRVRRVRR (SEQ ID NO:8);

RVRRVRRVRRVRR (SEQ ID NO:9);

RRWRRVRRVRRVRRVRRVRRVRRVRR (SEQ ID NO:10);

VRRVRRVRRVRRVRRVRRVRRVRRVRRVRRVRRVRRVRR (SEQ ID NO:11); and

RVRRVRRVRRVRRVRRVRRVRRVRRVRRVRRVRRVRRVRRVRRVRRVRR (SEQ ID NO:12).

Amend
40. A peptide-cargo complex comprising a cargo and a peptide selected from the group consisting of:

[RVIRVVQRACRAIRHIVRRIRQGLRRIL (SEQ ID NO: 1);

RVIRVVQRACRAIRHIVRRIRQGLRRILRVV (SEQ ID NO: 2);

RWIRVVQRCRAIRHIWRRIRQGLRRWLRVV (SEQ ID NO: 3);]

RVRRVRRVRRVRR (SEQ ID NO:4);

RRVRRVRRVRRVRRVRRVRRVRRVRR (SEQ ID NO: 5);

VRRVRRVRRVRRVRRVRRVRRVRRVRRVRRVRRVRRVRR (SEQ ID NO: 6);

RRVRRVRRVRRVRRVRRVRRVRRVRRVRRVRRVRRVRRVRRVRRVRR (SEQ ID NO:7);

RVRRVRRVRRVRRVRRVRRVRRVRRVRRVRRVRRVRRVRRVRRVRRVRR (SEQ ID NO:8);

RVRRVRRVRRVRR (SEQ ID NO:9);

RRWRRVRRVRRVRRVRRVRRVRRVRR (SEQ ID NO:10);

VRRVRRVRRVRRVRRVRRVRRVRRVRRVRRVRRVRRVRR (SEQ ID NO:11); and

RVRRVRRVRRVRRVRRVRRVRRVRRVRRVRRVRRVRRVRRVRRVRRVRR (SEQ ID NO:12).

42. A method for inhibiting the growth of a microbe comprising administering to a mammalian cell a microbial growth inhibiting effective amount of at least one peptide selected from the group consisting of:

[RVIRVVQACRAIRHIVRRIRQGLRRIL (SEQ ID NO: 1);
RVIRVVQACRAIRHIVRRIRQGLRRILRVV (SEQ ID NO: 2);
RWIRVVQRWCRAIRHIWRRIRQGLRRWLRVV (SEQ ID NO: 3);]
RVVRVVRRVVRR (SEQ ID NO:4);
RRVVRRVVRRVVRRVVRRVVRRVVRR (SEQ ID NO: 5);
VRRVVRRVVRRVVRRVVRRVVRRVVRRVVRRVVRRVVRR (SEQ ID NO: 6);
RRVVRRVVRRVVRRVVRRVVRRVVRRVVRRVVRRVVRRVVRR (SEQ ID NO:7);
RVVRVVRRVVRRVVRRVVRRVVRRVVRRVVRRVVRRVVRRVVRR (SEQ ID NO:8);
RVVRVVRRWVRR (SEQ ID NO:9);
RRWVRRVVRRVWRRVVRRVWRR (SEQ ID NO:10);
VRRVWRRVVRRVWRRVWRRVWRRVWRRVWRRVWRR (SEQ ID NO:11); and
RVVRVVRRWVRRVWRRVWRRVWRRVWRRVWRRVWRRVWRRVWRRVWRR (SEQ ID NO:12).

51. A method for suppressing HIV-1 infectivity comprising contacting a mammalian cell having HIV-1 with an HIV-1 infectivity suppressing effective amount of at least one peptide selected from the group consisting of:

[RVIRVVQRACRAIRHIVRRIRQGLRRIL (SEQ ID NO: 1);
RVIRVVQRACRAIRHIVRRIRQGLRRILRVV (SEQ ID NO: 2);
RWIRVVQRWCRAIRHIWRRIRQGLRRWLRVV (SEQ ID NO: 3);]
RVVRVVRRVVRR (SEQ ID NO:4);

RVVRVVRWVRRVRRVWRRVVRVVRWVRRVRRVWRRVVRVVRWV (SEQ ID NO:12).

63. A method for suppressing the infectivity of HIV-1 in a subject comprising contacting a cell of the subject with a HIV-1 infectivity suppressing effective amount of at least one peptide selected from the group consisting of:

[RVIRVVQRACRAIRHIVRRIRQGLRRIL (SEQ ID NO: 1);

RVIRVVQRACRAIRHIVRRIRQGLRRILRVV (SEQ ID NO: 2);

RWIRVVQRWCRAIRHIWRRIRQGLRRWLRVV (SEQ ID NO: 3);]

RVVRVVRVVR (SEQ ID NO:4);

RRVRRVRRVVRVVRVVRVVR (SEQ ID NO: 5);

VRRVRRVVRVVRVVRVVRVVRVVRVVRVVRVVRVVR (SEQ ID NO: 6);

RRVRRVRRVVRVVRVVRVVRVVRVVRVVRVVRVVRVVR (SEQ ID NO:7);

RVVRVVRVVRVVRVVRVVRVVRVVRVVRVVRVVRVVRVVRVVRVVR (SEQ ID NO:8);

RVVRVVRWVRR (SEQ ID NO:9);

RRWRRVRRVWRRVVRVVRWVRR (SEQ ID NO:10);

VRRVRRVVRVVRVVRVVRVVRVVRVVRVVRVVRVVR (SEQ ID NO:11); and

RVVRVVRWVRRVRRVWRRVVRVVRWVRRVRRVWRRVVRVVRWV (SEQ ID NO:12).